Origo Biopharma
Origo Biopharma was a Spanish clinical-stage biotech founded in 2017 developing a platform of locally-acting, organ-restricted TGF-beta inhibitors for fibrosis and cancer, with lead programmes in Crohn's disease-associated fibrostenosis, idiopathic pulmonary fibrosis and colorectal cancer. It had research facilities in Touro (A Coruña, Galicia) and corporate offices in Barcelona, and raised a €2.3M Series Seed round led by Sabadell Asabys with XesGalicia and the founding shareholders. The company was acquired by Belgian biotech Agomab Therapeutics in October 2021 and now operates as Agomab Spain, so it is no longer an independent startup. Its founders have since launched a successor biotech, Iteria Biopharma (2024), which closed a €5M seed round in April 2026 with Inveready and XesGalicia.
Founders
Global models
In the same niche 68 others
See all in the Start-ups Map →
Notes: Most funded first
Investors 3
Open as list →
Funding rounds 1
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2020-07-07 | Seed | €2.3M |
Asabys Partners
+3 more
|